Remove 2011 Remove Healthcare Remove Pharmaceutical manufacturing
article thumbnail

A Powerful Point-of-Sale Partnership that Delivers on the Promise of Affordable Insulin

PM360

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went into effect in May. for only $35. “We References: 1.

Retail 52
article thumbnail

Everything You Need to Know About Market Access in China

PM360

Given China’s status as the world’s second most populous nation and an economic powerhouse, it represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. In 2021, the out-of-pocket (OOP) cost accounts for 28% of the whole healthcare expenses compared to 15.4% billion people in 2023).

Marketing 105